Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%
Benchmarks Nifty22,705.85-47.36FEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.32 % Invest NowFEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.45 % Invest NowEnter search…
Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-year decline in revenue from operations, totaling Rs 7,404 crore. Additionally, a significant 26.7% decrease in EBITDA resulted in a lower margin of 18.7%. Nonetheless, Cipla's One India division demonstrated growth across various segments, while the company aims to enhance productivity and innovate its product offerings.
Listen to this article in summarized format
Loading...×Pharmaceuticals major Cipla on Tuesday reported a 35% year-on-year (YoY) decline in consolidated net profit to Rs 878 crore in Q2FY27, compared with Rs 1,351.17 crore in the corresponding quarter of the previous fiscal year.Revenue from operations dropped 2.4% YoY to Rs 7,404 crore in Q2FY27, compared with Rs 7,589.44 crore in the year-ago period, according to the exchange filing submitted by the company.
Cipla posted a 26.7% YoY decline in earnings before interest, taxes, depreciation and amortization (EBITDA) to Rs 1,388 crore in Q2FY27, compared with Rs 1,894.75 crore in the year-ago period.
EBITDA margin contracted to 18.7% in the quarter from 25% in the corresponding period last fiscal year.
Cipla’s One India business, meanwhile, saw growth across its segments. The branded prescription business recorded market growth of 15%, with respiratory, urology, cardiac, anti-diabetes and dermatology therapies witnessing strong double-digit market growth.
Live Events
The trade generics business delivered strong double-digit quarter-on-quarter (QoQ) growth, supported by portfolio expansion and the launch of more than 15 products during the quarter to address specific patient needs. In consumer health, brands such as Nicotex, Omnigel and Cipladine maintained their leadership positions in their respective market segments.
Cipla’s North America business reported quarterly revenue of $172 million, up $10 million from the previous quarter. Albuterol ranked No. 1 in the overall US Albuterol metered-dose inhaler (MDI) market, with a 22% market share.
The quarter also saw key regulatory and business developments in the US. The Food and Drug Administration (FDA) approved gAdvair Diskus, marking the first dry powder inhaler approval from Cipla’s US manufacturing network. The company also entered into an exclusive partnership with Qilu Pharmaceutical to commercialise a Keytruda biosimilar, strengthening its presence in oncology biosimilars.
In South Africa, Cipla’s secondary sales in the private market grew 6.5%, compared with overall market growth of 5%. Its prescription business maintained its No 2 position. The company's Emerging Markets and Europe (EMEU) business reported quarterly revenue of $101 million. Despite geopolitical uncertainties and market-specific headwinds, the business remained resilient, supported by strong execution and cost discipline across its direct-to-market (DTM) and business-to-business (B2B) segments.
Management Commentary
The pharmaceutical company said it remains focused on driving growth across its core businesses, improving productivity and strengthening its product pipeline.“We expect North America performance to remain supported by our upcoming product pipeline. South Africa’s private market business continued to outperform the market, growing approximately 1.3 times faster. We remain focused on serving patients with trusted, high-quality medicines,” said Achin Gupta, MD and Global CEO of Cipla.
Cipla share price
Cipla shares came under pressure following the Q2 results announcement, falling 3% to hit an intraday low of Rs 1,320 on the NSE, against the previous close of Rs 1,355. The pharma stock continued to trade lower on Tuesday.At around 1:48 PM, Cipla shares were trading at Rs 1,323.70, down 2.31% from the previous close on the NSE. So far in 2026, the stock has declined 12%, according to NSE data.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our ETMarkets WhatsApp channel)
Read More News onCipla Q2 ResultsCipla Q2 earningsCiplaQ2 ResultsCipla sharesmarkets news
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
...moreless(You can now subscribe to our ETMarkets WhatsApp channel)
Read More News onCipla Q2 ResultsCipla Q2 earningsCiplaQ2 ResultsCipla sharesmarkets news
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
...morelessPrime ExclusivesInvestment IdeasStock Report PlusePaperWealth EditionKYC and KYB: Inside Damani’s Avenue Supermarts that refuses to charge more – Part 1 of 3
Will oil turn into a lingering problem? Is the world economy, India, or the market prepared?
KYB and KYC: Business behind the wealth creator called ‘Divi’s Lab’ – Part 2, concluding
KYB and KYC: Business behind the wealth creator called “Divi’s Lab” – Part 1
The global business of promising more
One company, 2 words. Bond yield and CDS: Will they decide the fate of global markets?
- 1
- 2
- 3
& personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &
in-depth stock reportsSubscribe NowET
Unlock Access to All Exclusives with ETPrime FREE TRIAL
15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers
Trial offer expiring in00 : 05 : 00
I'd rather pay ₹2599 nowUh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Prime Account Detected!
It seems like you're already an ETPrime member with
Login using your ET Prime credentials to enjoy all member benefits
Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.
Unlock ETPrime's Exclusive Stories Today!
Big Price Drop! Flat 40% Off
Student Only OfferAlready a Member? Sign In nowAlready a Member? Sign In nowAlready a Member? Sign In nowOffer Exclusively For You
Save up to Rs. 700/-
ON ET PRIME MEMBERSHIP
Avail OfferOffer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail OfferOffer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail OfferOffer Exclusively For You
Get Flat 40% Off
Then ₹ 1749 for 1 year
Avail OfferOffer Exclusively For You
ET Prime at ₹ 49 for 1 month
Then ₹ 1749 for 1 year
Avail OfferSpecial Offer
Get flat 40% off on ETPrime
Avail OfferAvail OfferClaim NowAlready a Member? Sign In nowNeed Assistance?
Connect with an ETPrime expert for personalized support and guidance
+91 9484700004'; }); } if(listing) { var h3 = "You tried reading " + listArr.length + " locked stories in the past " + threshold + " days.", h4 = "Become an ET Prime member and don't miss out on these exclusive stories."; var html = '' + h3 + '
' + h4 + '
- ' + listing + '
What’s Included with
ETPrime Membership
1Exclusive Insights That Matter
Uncover the truth with our investigative stories
Make strategic moves using the real-world case studies
Read industry-specific stories to identify emerging trends
Spot opportunities with in-depth insights that matter
Trump temper on H-1B visas is forcing Indians to do these things to stay put in US
What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.
Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?
The problem with lab grown diamonds
Why a falling rupee is a better option for the economy
A list of top 20 momentum stocks that have delivered massive returns in one year
2Invest Wisely With Smart Market Tools & Investment Ideas
Alpha Trade
Get daily trade ideas from SEBI-registered research analysts.
Investment Ideas
Grow your wealth with stock ideas & sectoral trends.
Stock Reports Plus
All-in-one stock research with Stock Score, peer comparison & key signals.
BigBull Portfolio
Get to know where the market bulls are investing to identify the right stocks.
Stock Analyzer
Check the score based on the company's fundamentals, solvency, growth, risk & ownership to decide the right stocks.
Market Mood
Analyze the market sentiments & identify the trend reversal for strategic decisions.
Stock Talk Live at 9 AM Daily
Ask your stock queries & get assured replies by ET appointed, SEBI registered experts.
3Stay informed anytime, anywhere with ET ePaper
ePaper - Print View
Read the PDF version of ET newspaper. Download & access it offline anytime.
ePaper - Digital View
Read your daily newspaper in Digital View & get it delivered to your inbox everyday.
Wealth Edition
Manage your money efficiently with this weekly money management guide.
TOI ePaper
Read the PDF version of TOI newspaper. Download & access it offline anytime.
Deep Explainers
Explore the In-depth explanation of complex topics for everyday life decisions.
Health+ Stories
Get fitter with daily health insights committed to your well-being.
Personal Finance+ Stories
Manage your wealth better with in-depth insights & updates on finance.
5Enjoy Complimentary Subscriptions From Top Brands
Stream new documentaries from all across the world every day.
Stories you might be interested in
Figures reflect the source report and its stated period. This article is for information and is not investment advice.
